IKNA saw a nice PPS jump today. Looks like it was in response to IK-595 data presentation at the Plenary Session at AACR Special Conference on RAS Targeting. This is the RAS:RAF clamp that I mentioned previously. At first look IK-595 may be even better than VSTM's RAS:RAF clamp. That said VSTM is about two years ahead of IKNA and their drug VS-6766 (in combination with a FAK inhibitor) is showing very strong (breakthrough rated) data in LGSOC.
News 
Market Data 
Discover 
